Epiminder

Executive Summary

Epiminder is an Australian med-tech company that has developed Minder®, the world's first FDA-authorized implantable continuous EEG monitoring (iCEM) system. The device provides long-term, high-resolution brain activity data for patients with drug-resistant epilepsy, enabling remote care and improved treatment planning. With FDA authorization, Epiminder has cleared a critical regulatory hurdle, positioning itself as a pioneer in the neurology monitoring space. The company is currently in a clinical phase (Phase II) and is focused on gathering real-world evidence to support adoption and reimbursement. The drug-resistant epilepsy market is substantial, with over 30% of epilepsy patients not responding to medications, creating a strong need for advanced monitoring solutions. Epiminder's technology offers significant advantages over traditional EEG methods, including continuous data capture and patient convenience. The company is poised to capitalize on the growing trend toward remote patient monitoring and personalized neurology care. However, as a private company with limited public financial data, the investment case hinges on successful commercialization, market penetration, and securing reimbursement. Strategic partnerships with epilepsy centers and device distributors could accelerate adoption.

Upcoming Catalysts (preview)

• Q3 2026Completion of pivotal clinical study for US commercial launch70% success
• Q1 2027CMS reimbursement code assignment for iCEM60% success
• Q4 2026Strategic partnership with a major epilepsy center network75% success